1215 related articles for article (PubMed ID: 33303685)
1. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.
Baruch EN; Youngster I; Ben-Betzalel G; Ortenberg R; Lahat A; Katz L; Adler K; Dick-Necula D; Raskin S; Bloch N; Rotin D; Anafi L; Avivi C; Melnichenko J; Steinberg-Silman Y; Mamtani R; Harati H; Asher N; Shapira-Frommer R; Brosh-Nissimov T; Eshet Y; Ben-Simon S; Ziv O; Khan MAW; Amit M; Ajami NJ; Barshack I; Schachter J; Wargo JA; Koren O; Markel G; Boursi B
Science; 2021 Feb; 371(6529):602-609. PubMed ID: 33303685
[TBL] [Abstract][Full Text] [Related]
2. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients.
Davar D; Dzutsev AK; McCulloch JA; Rodrigues RR; Chauvin JM; Morrison RM; Deblasio RN; Menna C; Ding Q; Pagliano O; Zidi B; Zhang S; Badger JH; Vetizou M; Cole AM; Fernandes MR; Prescott S; Costa RGF; Balaji AK; Morgun A; Vujkovic-Cvijin I; Wang H; Borhani AA; Schwartz MB; Dubner HM; Ernst SJ; Rose A; Najjar YG; Belkaid Y; Kirkwood JM; Trinchieri G; Zarour HM
Science; 2021 Feb; 371(6529):595-602. PubMed ID: 33542131
[TBL] [Abstract][Full Text] [Related]
3. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
[TBL] [Abstract][Full Text] [Related]
4. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
Gopalakrishnan V; Spencer CN; Nezi L; Reuben A; Andrews MC; Karpinets TV; Prieto PA; Vicente D; Hoffman K; Wei SC; Cogdill AP; Zhao L; Hudgens CW; Hutchinson DS; Manzo T; Petaccia de Macedo M; Cotechini T; Kumar T; Chen WS; Reddy SM; Szczepaniak Sloane R; Galloway-Pena J; Jiang H; Chen PL; Shpall EJ; Rezvani K; Alousi AM; Chemaly RF; Shelburne S; Vence LM; Okhuysen PC; Jensen VB; Swennes AG; McAllister F; Marcelo Riquelme Sanchez E; Zhang Y; Le Chatelier E; Zitvogel L; Pons N; Austin-Breneman JL; Haydu LE; Burton EM; Gardner JM; Sirmans E; Hu J; Lazar AJ; Tsujikawa T; Diab A; Tawbi H; Glitza IC; Hwu WJ; Patel SP; Woodman SE; Amaria RN; Davies MA; Gershenwald JE; Hwu P; Lee JE; Zhang J; Coussens LM; Cooper ZA; Futreal PA; Daniel CR; Ajami NJ; Petrosino JF; Tetzlaff MT; Sharma P; Allison JP; Jenq RR; Wargo JA
Science; 2018 Jan; 359(6371):97-103. PubMed ID: 29097493
[TBL] [Abstract][Full Text] [Related]
6. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
[TBL] [Abstract][Full Text] [Related]
7. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
8. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
Kasanen H; Hernberg M; Mäkelä S; Brück O; Juteau S; Kohtamäki L; Ilander M; Mustjoki S; Kreutzman A
Cancer Immunol Immunother; 2020 May; 69(5):717-730. PubMed ID: 32036449
[TBL] [Abstract][Full Text] [Related]
9. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
10. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
11. CD103
Corgnac S; Malenica I; Mezquita L; Auclin E; Voilin E; Kacher J; Halse H; Grynszpan L; Signolle N; Dayris T; Leclerc M; Droin N; de Montpréville V; Mercier O; Validire P; Scoazec JY; Massard C; Chouaib S; Planchard D; Adam J; Besse B; Mami-Chouaib F
Cell Rep Med; 2020 Oct; 1(7):100127. PubMed ID: 33205076
[TBL] [Abstract][Full Text] [Related]
12. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
[TBL] [Abstract][Full Text] [Related]
14. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
[No Abstract] [Full Text] [Related]
15. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
Sivan A; Corrales L; Hubert N; Williams JB; Aquino-Michaels K; Earley ZM; Benyamin FW; Lei YM; Jabri B; Alegre ML; Chang EB; Gajewski TF
Science; 2015 Nov; 350(6264):1084-9. PubMed ID: 26541606
[TBL] [Abstract][Full Text] [Related]
16. The intimate relationship between gut microbiota and cancer immunotherapy.
Elkrief A; Derosa L; Zitvogel L; Kroemer G; Routy B
Gut Microbes; 2019; 10(3):424-428. PubMed ID: 30339501
[TBL] [Abstract][Full Text] [Related]
17. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
Front Immunol; 2021; 12():793831. PubMed ID: 34987517
[TBL] [Abstract][Full Text] [Related]
18. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
Narducci MG; Tosi A; Frezzolini A; Scala E; Passarelli F; Bonmassar L; Monopoli A; Accetturi MP; Cantonetti M; Antonini Cappellini GC; De Galitiis F; Rosato A; Picozza M; Russo G; D'Atri S
Front Immunol; 2020; 11():579894. PubMed ID: 33072126
[TBL] [Abstract][Full Text] [Related]
19. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
20. Microbiota Manipulated to Enhance Immunity.
Cancer Discov; 2019 Jul; 9(7):822. PubMed ID: 31072874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
